RSV in Older Adults Riskier Than Realized; Vaccine Could Help

A new model suggests that as many as 4.8 million symptomatic cases of respiratory syncytial virus (RSV) occur in the United States among patients 65 and older. That burden is greater than previously recognized, according to another study, which looked at the U.S. and other high-income countries. Recently approved vaccines are likely to be game-changers.